Description
Proven protection, proven performance
- Demonstrated CIED stabilization and infection reduction1–9
- Locally-delivered minocycline and rifampin sustained for 7 days10
- Polymer-controlled antibiotic elution10
- Multifilament-knitted mesh fully absorbs in approximately 9 weeks10,11
- Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019;380(20):1895–1905.
- Huntingdon Life Sciences study TR-2011-054.
- Osoro M, Lorson W, Hirsh JB, Mahlow WJ. Use of an antimicrobial pouch/envelope in the treatment of Twiddler’s syndrome. Pacing Clin Electrophysiol. 2018;41(2):136–142.
- Bloom HL, Constantin L, Dan D, et al. Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. Pacing Clin Electrophysiol. 2011;34(2):133–142.
- Mittal S, Shaw RE, Michel K, et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm. 2014;11(4):595–601.
- Kolek MJ, Patel NJ, Clair WK, et al. Efficacy of a bio-absorbable antibacterial envelope to prevent cardiac implantable electronic device Infections in high-risk subjects. J Cardiovasc Electrophysiol. 2015;26(10):1111–1116.
- Shariff N, Eby E, Adelstein E, et al. Health and economic outcomes associated with use of an antimicrobial envelope as a standard of care for cardiac implantable electronic device implantation. J Cardiovasc Electrophysiol. 2015;26(7):783–789.
- Henrikson CA, Sohail MR, Acosta H, et al. Antibacterial envelope is associated with low infection rates after implantable cardioverter-defibrillator and cardiac resynchronization therapy device replacement: Results of the Citadel and Centurion studies. JACC Clin Electrophysiol. 2017;3(10):1158–1167.
- Kolek MJ, Dresen WF, Wells QS, Ellis CR. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol. 2013;36(3):354–361.
- Huntingdon Life Sciences study TR-2013–001.
- Sinclair Labs study D13599.
Not what you're looking for?
Find more information, including other available configurations, for TYRX™ absorbable antibacterial envelope.